LYNDON LEWIS: Open Payments
NPI 1942877766 · LONGVIEW, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,229 in 133 payments from 17 companies in 2025. Trend: 2023 $2,248 · 2024 $2,492 · 2025 $3,229
Food & beverage: $3,229
| Company | Payments | Amount |
|---|---|---|
| CSL Behring | 37 | $944 |
| AstraZeneca Pharmaceuticals LP | 23 | $533 |
| GENZYME CORPORATION | 12 | $296 |
| Amgen Inc. | 11 | $281 |
| Regeneron Healthcare Solutions, Inc. | 11 | $238 |
| Novartis Pharmaceuticals Corporation | 8 | $205 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $170 |
| GlaxoSmithKline, LLC. | 10 | $167 |
| Genentech USA, Inc. | 3 | $93 |
| Pharming Healthcare, Inc. | 3 | $79 |
Products named: TEZSPIRE, DUPIXENT, Hizentra, Haegarda, Andembry, XOLAIR, AIRSUPRA, CUVITRU.
Industry payments across WA — which companies pay providers there.
